The binary event is the CHAPTER-3 topline data expected within the next ~6 weeks. A positive readout would validate the XR prophylaxis program and significantly de-risk the pipeline, while a negative or mixed result would be a major setback. Traders should position for high volatility around the data release, with the PDUFA date in April 2027 providing a longer-term catalyst.
Price Chart
Executive Summary
Pharvaris reported Q2 2026 financial results with no revenue, a net loss of €47.8M (€0.70/share), and cash of €318M. The key catalyst is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, alongside the ongoing FDA review of the deucrictibant IR NDA with a PDUFA date of April 23, 2027. The May 2026 $132M offering extends the cash runway into 2028, funding pre-commercial activities and lifecycle management, but the pre-revenue stage and increasing operating losses keep the stock binary on pipeline execution.
Key Facts
- No revenue generated for Q2 2026 or Q2 2025.
- Net loss of €47.8M for Q2 2026 vs €45.5M for Q2 2025.
- Cash and cash equivalents of €318M as of June 30, 2026, up from €292M at Dec 31, 2025.
- Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026.
- Deucrictibant IR NDA under FDA review with PDUFA date of April 23, 2027; MAA validated by EMA in July 2026.
- Closed a $132.3M underwritten offering in May 2026, extending cash runway into 2028.
- R&D expenses increased 18% YoY to €35.0M; G&A expenses increased 47% YoY to €15.8M.
- Enrollment ongoing in CREAATE, a pivotal Phase 3 study for AAE-C1INH.
Financial Impact
Net loss of €47.8M in Q2 2026, with cash burn of €86.6M in operating activities for H1 2026. Cash runway extended into 2028 via $132.3M May 2026 offering.
Risk Factors
- CHAPTER-3 Phase 3 data may fail to meet primary or key secondary endpoints.
- FDA may not approve deucrictibant IR NDA by the PDUFA date or at all.
- Increasing operating losses and cash burn rate may require additional dilutive financing before reaching profitability.
- Competition from existing HAE therapies (e.g., Takhzyro, Orladeyo) could limit commercial uptake if approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-345702 |
| Document: phvs-ex99_2.htm | 0001193125-26-345702 |
| Document: phvs-20260630.htm | 0001193125-26-345702 |
| Document: phvs-ex99_1.htm | 0001193125-26-345702 |
| Document: 0001193125-26-345702-index-headers.html | 0001193125-26-345702 |
| Document: 0001193125-26-345702-index.html | 0001193125-26-345702 |
| Document: 0001193125-26-345702.txt | 0001193125-26-345702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access